Route of administration- Subcutaneous Injection

2 trials

Sponsors

Intas Pharmaceuticals Limited, Intas Pharmaceutical Limited Biopharma Division

Conditions

Health Condition 1: D693- Immune thrombocytopenic purpuraHealth Condition 1: M810- Age-related osteoporosis without current pathological fracture

Phase 3

A study of Denosumab in patients.

Active, not recruitingCTRI/2021/09/036190

Intas Pharmaceutical Limited Biopharma DivisionHealth Condition 1: M810- Age-related osteoporosis without current pathological fracture

Target: 552Updated: 2023-05-01

Phase 4

A study of Romiplostim Powder for Injection in patients

Active, not recruitingCTRI/2021/08/035609

Intas Pharmaceuticals LimitedHealth Condition 1: D693- Immune thrombocytopenic purpura

Target: 25Updated: 2022-10-17